Gutkind JS - Search Results

1

Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.

Baqai U, Kurimchak AM, Trachtenberg IV, Purwin TJ, Haj JI, Han A, Luo K, Pachon NF, Jeon A, Chua V, Davies MA, Gutkind JS, Benovic JL, Duncan JS, Aplin AE. Baqai U, et al. Among authors: gutkind js. J Biol Chem. 2023 Dec;299(12):105418. doi: 10.1016/j.jbc.2023.105418. Epub 2023 Nov 3. J Biol Chem. 2023. PMID: 37923138 Free PMC article.

2

Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry.

Arang N, Lubrano S, Rigiracciolo DC, Nachmanson D, Lippman SM, Mali P, Harismendy O, Gutkind JS. Arang N, et al. Among authors: gutkind js. J Biol Chem. 2023 Feb;299(2):102866. doi: 10.1016/j.jbc.2022.102866. Epub 2022 Dec 31. J Biol Chem. 2023. PMID: 36596361 Free PMC article.

3

Gαs is dispensable for β-arrestin coupling but dictates GRK selectivity and is predominant for gene expression regulation by β2-adrenergic receptor.

Burghi V, Paradis JS, Officer A, Adame-Garcia SR, Wu X, Matthees ESF, Barsi-Rhyne B, Ramms DJ, Clubb L, Acosta M, Tamayo P, Bouvier M, Inoue A, von Zastrow M, Hoffmann C, Gutkind JS. Burghi V, et al. Among authors: gutkind js. J Biol Chem. 2023 Nov;299(11):105293. doi: 10.1016/j.jbc.2023.105293. Epub 2023 Sep 27. J Biol Chem. 2023. PMID: 37774973 Free PMC article.

4

High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.

Arang N, Lubrano S, Ceribelli M, Rigiracciolo DC, Saddawi-Konefka R, Faraji F, Ramirez SI, Kim D, Tosto FA, Stevenson E, Zhou Y, Wang Z, Bogomolovas J, Molinolo AA, Swaney DL, Krogan NJ, Yang J, Coma S, Pachter JA, Aplin AE, Alessi DR, Thomas CJ, Gutkind JS. Arang N, et al. Among authors: gutkind js. Cell Rep Med. 2023 Nov 21;4(11):101244. doi: 10.1016/j.xcrm.2023.101244. Epub 2023 Oct 18. Cell Rep Med. 2023. PMID: 37858338 Free PMC article.

5

Pan-Cancer Analysis of Patient Tumor Single-Cell Transcriptomes Identifies Promising Selective and Safe Chimeric Antigen Receptor Targets in Head and Neck Cancer.

Madan S, Sinha S, Chang T, Gutkind JS, Cohen EEW, Schäffer AA, Ruppin E. Madan S, et al. Among authors: gutkind js. Cancers (Basel). 2023 Oct 8;15(19):4885. doi: 10.3390/cancers15194885. Cancers (Basel). 2023. PMID: 37835579 Free PMC article.

6

CHMP2A regulates broad immune cell-mediated antitumor activity in an immunocompetent in vivo head and neck squamous cell carcinoma model.

Yun J, Saddawi-Konefka R, Goldenson B, Al-Msari R, Bernareggi D, Thangaraj JL, Tang S, Patel SH, Luna SM, Gutkind JS, Kaufman D. Yun J, et al. Among authors: gutkind js. J Immunother Cancer. 2024 May 3;12(5):e007187. doi: 10.1136/jitc-2023-007187. J Immunother Cancer. 2024. PMID: 38702144 Free article.

7

Gα12 signaling regulates transcriptional and phenotypic responses that promote glioblastoma tumor invasion.

Chaim OM, Miki S, Prager BC, Ma J, Jeong AY, Lara J, Tran NK, Smith JM, Rich JN, Gutkind JS, Miyamoto S, Furnari FB, Brown JH. Chaim OM, et al. Among authors: gutkind js. Sci Rep. 2023 Dec 16;13(1):22412. doi: 10.1038/s41598-023-49164-4. Sci Rep. 2023. PMID: 38104152 Free PMC article.

8

AXL activates YAP through the EGFR-LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma.

Okamoto K, Ando T, Izumi H, Kobayashi SS, Shintani T, Gutkind JS, Yanamoto S, Miyauchi M, Kajiya M. Okamoto K, et al. Among authors: gutkind js. Oncogene. 2023 Sep;42(39):2869-2877. doi: 10.1038/s41388-023-02810-7. Epub 2023 Aug 17. Oncogene. 2023. PMID: 37591955

9

Akt Is Controlled by Bag5 through a Monoubiquitination to Polyubiquitination Switch.

Bracho-Valdés I, Cervantes-Villagrana RD, Beltrán-Navarro YM, Olguín-Olguín A, Escobar-Islas E, Carretero-Ortega J, Olivares-Reyes JA, Reyes-Cruz G, Gutkind JS, Vázquez-Prado J. Bracho-Valdés I, et al. Among authors: gutkind js. Int J Mol Sci. 2023 Dec 15;24(24):17531. doi: 10.3390/ijms242417531. Int J Mol Sci. 2023. PMID: 38139359 Free PMC article.

10

Integrating Genetic Alterations and the Hippo Pathway in Head and Neck Squamous Cell Carcinoma for Future Precision Medicine.

Ando T, Okamoto K, Shintani T, Yanamoto S, Miyauchi M, Gutkind JS, Kajiya M. Ando T, et al. Among authors: gutkind js. J Pers Med. 2022 Sep 20;12(10):1544. doi: 10.3390/jpm12101544. J Pers Med. 2022. PMID: 36294681 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

531 results

Search Page